Navigation Links
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Date:11/2/2009

"safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the intended use and sufficiency of the Company's cash, cash equivalents and short-term investments, the company's manufacturing and clinical trial readiness, prospects for securing a co-development and commercialization partner and planned phase 3 trials. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome ... use its proprietary methodologies and expertise in genomic ... kinase targets in collaboration with Blueprint Medicines.  PGDx ... at identifying genomic alterations in tumors, and Blueprint ... kinase inhibitors for a genetically defined patient population. ...
(Date:5/21/2013)... May 21, 2013 Inflamax scientists ... the ITN to design the study, which will ... key clinical models used in the study of ... Nasal Allergen Challenge (NAC) models. Although both the ... publications, to date no direct comparison between the ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 PathoGenetix, ... rapid bacterial strain typing, announced today that it has ... pathogenic E. coli strains obtained from the Centers for ... Sequence Scanning™ (GSS™) technology. The findings are detailed in ... of the American Society for Microbiology in Denver on ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
... Calif. and BANGALORE, India, July 10, 2011 Life ... that it has launched a regional distribution hub in India ... The new India Distribution Center (IDC), located ... of Life Technologies, products to its thousands of customers in ...
... NATICK, Mass., July 8, 2011 RegenoCELL Therapeutics, Inc. (OTCBB: ... pleased to announce the opening of another state of the ... congestive heart failure and peripheral artery disease with its autologous ... congestive heart failure is administered at the Metropolitan Hospital in ...
... Care Compliance Strategies, Inc. (HCCS) announced today a partnership ... to deliver a series of critical care nursing and ... Management Systems.  This training includes two separate AACN courses: ... Essentials of Nurse Manager Orientation . The courses ...
Cached Biology Technology:Life Technologies Launches New Distribution Center in India 2Life Technologies Launches New Distribution Center in India 3RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 2RegenoCELL Announces That Patients Can Be Treated With Its Autologous Stem Cell Therapy in Greece 3HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 2HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training 3
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... New research suggests that a compound abundant in the ... death. , By altering a very specific step ... into normal cells that die as scheduled. , One ... process that would cause them to die on a ... study in cells, led by Ohio State University researchers, ...
(Date:5/20/2013)... study conducted at the University of Bristol and published ... sheds light on how the brain and inner ... Bristol,s School of Earth Sciences, together with Tom Hbner ... brains of 150 million year old dinosaurs. , The ... Dysalotosaurus lettowvorbecki : a very young (juvenile) individual ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3Fossil brain teaser 2
... University of Santiago de Compostela (USC) have studied the ... show that the principal goal of young people is ... antisocial among them place greater importance on popularity with ... on are to do with leaving home, work and ...
... ulcers, one of the ,neglected tropical diseases, left aside by ... in poor regions. But then more attention has to be ... rules of the World Health Organization urgently need to be ... Medicine (ITM), based on ten years of research in Congo. ...
... This release is available in Spanish . ... receive--in addition to what foods you eat--all can influence the ... for optimum health. In a preliminary and apparently first-of-its-kind study, ... colleagues have developed a preliminary model that predicts an individual,s ...
Cached Biology News:Teenagers want to finish their studies and leave home 2WHO guidelines on Buruli ulcer need adjustment 2Model predicts individual's vitamin D needs 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Biology Products: